{"id":"W1992008940","doi":"10.1097/qad.0b013e32832d3b54","title":"Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy","year":2009,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Gilead Sciences; GlaxoSmithKline; Bristol-Myers Squibb; Medical Research Council; Abbott Laboratories; European Commission; Pfizer; National Institutes of Health; National Science Foundation","keywords":"Nevirapine; Antiretroviral therapy; Medicine; Limiting; Oncology; Virology; Internal medicine; Intensive care medicine; Human immunodeficiency virus (HIV); Pharmacology; Viral load","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001411898,0.0002539176,0.000417992,0.0002034383,0.0001464867,0.00002887742,0.00004887044,0.00006857089,0.00002330603],"category_scores_gemma":[0.0001157682,0.0001877048,0.000147095,0.0001748796,0.00002089466,0.0001573264,0.000008350517,0.00006922438,0.000006095986],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002401589,"about_ca_system_score_gemma":0.00005613866,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006941113,"about_ca_topic_score_gemma":0.000005729547,"domain_scores_codex":[0.9987238,0.00004008818,0.0003628768,0.0002780223,0.0001728016,0.0004224174],"domain_scores_gemma":[0.9994407,0.0001472629,0.0001276323,0.0001529775,0.00004858274,0.0000828071],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003231812,0.0003274202,0.853516,0.000004982248,0.00009572187,0.000006097498,0.00331075,0.000003642212,0.0001637548,0.0000536901,0.00003593901,0.1421588],"study_design_scores_gemma":[0.0161952,0.01248694,0.9533154,0.0001406059,0.0001133693,6.41232e-7,0.0025393,0.0002544785,0.01349489,0.0002595411,0.0008531734,0.0003463909],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979686,0.0001871599,0.00005088101,0.000164068,0.00007207805,0.0007300962,0.00001792828,0.0000803857,0.0007288077],"genre_scores_gemma":[0.9959795,0.0001094186,0.002331286,0.0001976724,0.00007814011,0.0000351987,0.0001536724,0.00002433537,0.001090723],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1418124,"threshold_uncertainty_score":0.7654379,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0242688332906109,"score_gpt":0.2753207164001895,"score_spread":0.2510518831095785,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}